 |
|
|
| |
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
|
| |
| |
- Key Insights from Viral Hepatitis, PBC, and MASH/Fibrosis Studies Highlight Gilead's Ongoing Commitment to Advancing Life-Changing Liver Disease Research -
FOSTER CITY, Calif.-Oct 22, 2024 (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting • 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif. More than 40 abstracts will be presented with key data, including 11 abstracts reporting new data on primary biliary cholangitis (PBC). The data will include findings from the RESPONSE trial that demonstrate the efficacy and safety profile of Livdelzi • (seladelpar) in people living with PBC and compensated cirrhosis. Additionally, data will be presented on the effects of Livdelzi on pruritus (chronic itching), a symptom that has significant impact on the quality of life of people living with PBC, along with interim long-term efficacy and safety results from the ongoing ASSURE study.
Beyond PBC, Gilead will be presenting an interim analysis of the Phase 3 MYR301 study, which is evaluating people living with hepatitis Delta virus (HDV) who received bulevirtide monotherapy (2 mg for 144 weeks; 10 mg for 144 weeks; or 10 mg for 96 weeks) for chronic HDV and have been off treatment for 48 weeks. The study is evaluating whether or not patients treated with bulevirtide monotherapy for 2-3 years maintained virological and biochemical responses one year after stopping treatment. An additional 144-week analysis of patient-reported outcomes for individuals treated with bulevirtide 2 mg will also be presented, adding to the wealth of long-term data for the treatment for chronic HDV.
"We're excited to share our latest research at The Liver Meeting, as we push the boundaries of what's possible in liver disease treatment. The breadth of this research reflects Gilead's unwavering dedication to advancing life-changing science and shaping healthier futures for people living with liver disease," said Anu Osinusi, Vice President of Clinical Development for Hepatitis, Respiratory and Emerging Viruses, Gilead Sciences. "The depth and range of our data, spanning both viral and inflammatory liver diseases, underscores our commitment to making a meaningful impact at every stage of a person's journey in liver disease. Our goals go far beyond treatment alone-our work spans awareness, education, screening, diagnosis, and long-term care, all intending to address unmet needs and enhance treatment outcomes."
Gilead will also present hepatitis C virus (HCV) data which will include safety and tolerability outcomes for Epclusa • (velpatasvir/sofosbuvir) in pregnant individuals with chronic HCV (the STORC study). As a special population that is often excluded from clinical research, these results may help clinicians better support pregnant people living with HCV, which in turn may reduce the risk of transmission to infants. Furthermore, real-world findings from the SVR10K study on HCV will be showcased, demonstrating the effects of direct-acting antivirals against all HCV genotypes across diverse regions. Late-breaking data from a Phase 2a open-label study assessing the safety and efficacy of novel combination therapies for chronic hepatitis B virus (HBV) will also be presented by Gilead.
Full press release link:
https://www.gilead.com/news/news-details/2024/gilead-to-present-latest-research-across-key-liver-disease-indication-at-the-american-association-for-the-study-of-liver-disease-aasld-meeting-2024
|
| |
|
|
|
|
|
